Armando Santoro

73PUBLICATIONS
480CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (73)

|Jul 02, 2026
Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

|Jun 25, 2026
Development and Preliminary Validation of a Tool to Assess Barriers and Facilitators to Participation in Adjuvant Endocrine Therapy Switch Trials.

|Feb 26, 2026
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca

|Jan 22, 2026
Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.

Filippo Bagnoli, Jacopo Calabrese De Feo, Francesca Ricci

|Jan 10, 2026
Correction: Cecchi et al. Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions. Cancers 2025, 17, 3199.

Luigi Giovanni Cecchi, Marta Aliprandi, Fabio De Vincenzo

|Jan 07, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Noffar Bar, Thomas Martin, Craig C Hofmeister

Pageof 13

Frequent Collaborators

16 joint publications

Rita De Sanctis

10 joint publications

Paola Tiberio

9 joint publications

Alberto Zambelli

8 joint publications

Pier Luigi Zinzani